Generation Bio to Present at the 2022 Jefferies Healthcare Conference
Generation Bio (Nasdaq: GBIO) will have CEO Geoff McDonough participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 10th at 11:00 a.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO) will have CEO Geoff McDonough participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 10th at 11:00 a.m. ET in New York. A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for 30 days afterwards.
The company focuses on innovative genetic medicines for rare and prevalent diseases using a unique DNA construct and delivery system aimed at providing durable treatments.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +3.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 11:00 a.m. ET in New York.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.